Abstract
This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 23 participants less than or equal to (<=) 50 years of age with transfusion-dependent -thalassemia tdt also known as -thalassemia major who do not have a 0 mutation at both alleles of the hemoglobin hbb gene. the study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation hsct using lentiglobin bb305 drug product.>
